memo (2009) Vol. 2: 63
 DOI 10.1007/s12254-009-0122-x
 Printed in Austria
 © Springer-Verlag 2009

Central European Cooperative Oncology Group

Initiation of the TURANDOT breast cancer study

The following CECOG-protocol is open for patient enrolment:

CECOG/BC.1.3.005 – TURANDOT

Capeci **T** abine and
 Bevaciz **U** mab
R andomized
A gainst
 Avasti **N**
 an **D**
 tax **O** l
T rial

A randomized phase III 2-arm trial of paclitaxel plus bevacizumab vs. capecitabine plus bevacizumab for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancer.

Principal Investigator: Prof. Christoph Zielinski, M.D.
Vice-Coordinator: Thomas Brodowicz, M.D.,
 Associate Professor
Sponsor: CECOG

Participating countries: Austria, Bosnia, Bulgaria, Croatia, Czech Republic, Hungary, Israel, Latvia, Poland, Romania, Serbia and Slovakia.

This study requires **490 eligible patients**. Assuming an exclusion rate of up to 12% from the per-protocol population, 560 eligible patients need to be recruited. The recruitment of patients started in September 2008.

If you are interested to learn more about this trial, please contact CECOG, attn. Dagmar Just (dagmar.just@cecog.at). Against receipt of a signed confidentiality agreement you will be supplied with further trial-related details.

For information about **all CECOG activities** please visit our homepage under www.cecog.org.

Christoph Zielinski
 President

Thomas Brodowicz
 Director

CECOG
 Dagmar Just
 Central European Cooperative Oncology Group (CECOG)
 Schlagergasse 6/6
 1090 Wien
 Austria
 Phone: +43/1/409 77 11
 Fax: +43/1/409 77 26
 E-mail: cecog@cecog.at
 Website: www.cecog.org